Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials

There is currently no cure for Dry Eye Disease. Existing treatments are often not enough to control discomfort for moderate to severe patients unless there is a way to further speed up the healing process.

Through its multi-modal mechanism of action, BRIM’s novel regenerative peptide therapy, BRM421, has the potential to break the vicious cycle of corneal damage in Dry Eye Disease, offering patients rapid and total relief.

A recent article in the Feb/March edition of Eye News Magazine shared the news that BRM421 has advanced to Phase 3 clinical trials. Enrolment is currently underway for more than 700 patients with moderate to severe DED. The multi-centre, double-blind, randomised, placebo-controlled trial in the US, is expected to be completed in Q4 2023.

Read the full article using the link below to discover more.

This article was published in the Dry Eye Supplement of Eye News magazine in Feb/Mar 2023.

Dry Eye Supplement:

Eye News Magazine: